What information must be described about investigational products?

• A. The dosage regimen only
• B. Data management plan
• C. The dosage form, packaging, and labeling
• D. The marketing plan

Answer: (C)

Describing investigational products focuses on how the product is presented and identified to ensure safe, accurate use and clear traceability. Knowing the dosage form (what the product is in) and its strength, along with packaging and labeling details, ensures investigators and participants receive the correct product, that containers are not confused, and that lot numbers, storage instructions, expiry dates, and trial identifiers are consistently captured. This information supports proper administration, storage conditions, accountability, and regulatory compliance throughout the trial. The dosage regimen matters for how much and how often to give, but it doesn’t fully describe the product’s physical presentation or identification. The data management plan covers data handling, and the marketing plan is not related to how the investigational product is presented or stored.